PL1725872T3 - Analiza szczepionek sacharydowych bez interferencji - Google Patents

Analiza szczepionek sacharydowych bez interferencji

Info

Publication number
PL1725872T3
PL1725872T3 PL05718447T PL05718447T PL1725872T3 PL 1725872 T3 PL1725872 T3 PL 1725872T3 PL 05718447 T PL05718447 T PL 05718447T PL 05718447 T PL05718447 T PL 05718447T PL 1725872 T3 PL1725872 T3 PL 1725872T3
Authority
PL
Poland
Prior art keywords
saccharide
serogroup
batch
concentration
interference
Prior art date
Application number
PL05718447T
Other languages
English (en)
Inventor
Angela Bardotti
Daniela Proietti
Stefano Ricci
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32117883&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1725872(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL1725872T3 publication Critical patent/PL1725872T3/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/22—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Neisseriaceae (F), e.g. Acinetobacter
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Saccharide Compounds (AREA)
  • Seasonings (AREA)
PL05718447T 2004-03-17 2005-03-17 Analiza szczepionek sacharydowych bez interferencji PL1725872T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0406013.3A GB0406013D0 (en) 2004-03-17 2004-03-17 Analysis of saccharide vaccines without interference
EP05718447A EP1725872B8 (en) 2004-03-17 2005-03-17 Analysis of saccharide vaccines without interference
PCT/IB2005/000987 WO2005090986A2 (en) 2004-03-17 2005-03-17 Analysis of saccharide vaccines without interference

Publications (1)

Publication Number Publication Date
PL1725872T3 true PL1725872T3 (pl) 2011-06-30

Family

ID=32117883

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05718447T PL1725872T3 (pl) 2004-03-17 2005-03-17 Analiza szczepionek sacharydowych bez interferencji

Country Status (18)

Country Link
US (3) US20080305126A1 (pl)
EP (4) EP2290366A1 (pl)
JP (2) JP4692852B2 (pl)
CN (1) CN1981195B (pl)
AT (2) ATE500510T1 (pl)
AU (2) AU2005224459B2 (pl)
BR (1) BRPI0508890A (pl)
CA (1) CA2560224C (pl)
CY (1) CY1111272T1 (pl)
DE (2) DE602005024523D1 (pl)
ES (1) ES2353701T3 (pl)
GB (1) GB0406013D0 (pl)
NZ (2) NZ570193A (pl)
PL (1) PL1725872T3 (pl)
PT (1) PT1725872E (pl)
RU (1) RU2371725C2 (pl)
SI (1) SI1725872T1 (pl)
WO (2) WO2005090985A1 (pl)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0411387D0 (en) * 2004-05-21 2004-06-23 Chiron Srl Analysis of saccharide length
GB0524782D0 (en) * 2005-12-05 2006-01-11 Chiron Srl Analysis of samples
GB0605757D0 (en) * 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
GB0612854D0 (en) 2006-06-28 2006-08-09 Novartis Ag Saccharide analysis
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
US8797995B2 (en) * 2007-01-18 2014-08-05 Cisco Technology, Inc. Device-assisted layer 3 handoff for mobile services
GB0713880D0 (en) * 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
US8207298B2 (en) * 2008-05-01 2012-06-26 Archemix Corp. Methods of separating biopolymer conjugated molecules from unconjugated molecules
TW201009337A (en) * 2008-05-30 2010-03-01 Intervet Int Bv Analytical method to monitor vaccine potency and stability
US20100098021A1 (en) * 2008-10-16 2010-04-22 Cisco Technology, Inc. Policy-driven layer 3 handoff for mobile services
CA2791418C (en) * 2010-03-10 2016-07-05 Inovobiologic, Inc. Food comprising glucomannan, xanthan gum and alginate for the treatment of metabolic disorders
CA2808975C (en) 2010-08-23 2018-10-30 Wyeth Llc Stable formulations of neisseria meningitidis rlp2086 antigens
KR101584871B1 (ko) 2010-09-10 2016-01-22 와이어쓰 엘엘씨 네이세리아 메닝기티디스 orf2086 항원의 비-지질화된 변이체
CA2865745C (en) 2012-03-09 2018-01-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
EP2852414B9 (en) 2012-05-22 2020-12-09 GlaxoSmithKline Biologicals SA Meningococcus serogroup x conjugate
CN102735809B (zh) * 2012-06-29 2015-04-29 成都欧林生物科技股份有限公司 测定Hib结合疫苗中高分子结合物含量的方法
CA2903716C (en) 2013-03-08 2019-04-09 Pfizer Inc. Immunogenic fusion polypeptides
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
CZ2014451A3 (cs) 2014-06-30 2016-01-13 Contipro Pharma A.S. Protinádorová kompozice na bázi kyseliny hyaluronové a anorganických nanočástic, způsob její přípravy a použití
KR20190049940A (ko) 2015-02-19 2019-05-09 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
CZ309295B6 (cs) 2015-03-09 2022-08-10 Contipro A.S. Samonosný, biodegradabilní film na bázi hydrofobizované kyseliny hyaluronové, způsob jeho přípravy a použití
CZ2015398A3 (cs) 2015-06-15 2017-02-08 Contipro A.S. Způsob síťování polysacharidů s využitím fotolabilních chránicích skupin
CZ306662B6 (cs) 2015-06-26 2017-04-26 Contipro A.S. Deriváty sulfatovaných polysacharidů, způsob jejich přípravy, způsob jejich modifikace a použití
CZ308106B6 (cs) 2016-06-27 2020-01-08 Contipro A.S. Nenasycené deriváty polysacharidů, způsob jejich přípravy a jejich použití
SG11201906519RA (en) 2017-01-31 2019-08-27 Pfizer Neisseria meningitidis compositions and methods thereof
CA3108739A1 (en) 2018-08-06 2020-02-13 Nielsen Biosciences, Inc. Treatment of warts
CA3155669A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
EP4038369B1 (en) 2019-10-01 2026-03-04 Biological E Limited Methods for quantification of carbohydrates

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB323103A (en) 1928-12-07 1929-12-24 Fred Cunningham Firth Improvements relating to shaper mechanism for winding yarn on weft bobbins in spinning mules
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
US4663160A (en) 1983-03-14 1987-05-05 Miles Laboratories, Inc. Vaccines for gram-negative bacteria
US4761283A (en) 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
JPH01125328A (ja) 1987-07-30 1989-05-17 Centro Natl De Biopreparados 髄膜炎菌ワクチン
NL8802046A (nl) 1988-08-18 1990-03-16 Gen Electric Polymeermengsel met polyester en alkaansulfonaat, daaruit gevormde voorwerpen.
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
CA2006700A1 (en) 1989-01-17 1990-07-17 Antonello Pessi Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
AU651949B2 (en) 1989-07-14 1994-08-11 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
DE69130136T2 (de) * 1990-06-21 1999-03-11 Oxford Glycosciences (Uk) Ltd., Abingdon, Oxon Automatisiertes Verfahren zur Spaltung von Biomolekülen
ATE128628T1 (de) 1990-08-13 1995-10-15 American Cyanamid Co Faser-hemagglutinin von bordetella pertussis als träger für konjugierten impfstoff.
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
CA2142981C (en) 1992-08-31 2007-10-23 Joseph Y. Tai Vaccines against group c neisseria meningitidis
US5425946A (en) 1992-08-31 1995-06-20 North American Vaccine, Inc. Vaccines against group C Neisseria meningitidis
NZ311000A (en) 1995-06-07 1999-04-29 Smithkline Beecham Biolog Vaccine comprising a polysaccharide antigen-carrier protein conjugate and a free carrier protein
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
JP4435413B2 (ja) * 1997-12-23 2010-03-17 バクスター・ヘルスケヤー・ソシエテ・アノニム ワクチンとしてまたは結合体ワクチンとしてタンパク質に連結して使用するための細菌莢膜多糖の抽出および単離法
US7018637B2 (en) * 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
WO1999047174A1 (en) 1998-03-18 1999-09-23 Cambridge Biostability Limited Amorphous glasses for stabilising sensitive products
CN1263510C (zh) 1998-08-19 2006-07-12 巴克斯特健康护理股份有限公司 多糖－蛋白质缀合物或寡糖－蛋白质缀合物、其制备方法及其应用
CA2366152A1 (en) 1999-03-19 2000-09-28 Smithkline Beecham Biologicals S.A. Streptococcus pneumoniae vaccine
FR2791895B1 (fr) 1999-03-23 2001-06-15 Pasteur Merieux Serums Vacc Utilisation de trehalose pour stabiliser un vaccin liquide
WO2000061761A2 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
ES2588917T3 (es) 2000-01-17 2016-11-07 Glaxosmithkline Biologicals Sa Vacuna de VME suplementada contra meningococo
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
MXPA03000822A (es) 2000-07-27 2004-11-01 Childrens Hosp & Res Ct Oak Vacunas para proteccion de espectro amplio contra enfermedades causadas por neisseria meningitidis.
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
CA2435681C (en) * 2001-01-23 2011-06-21 Aventis Pasteur Multivalent meningococcal polysaccharide-protein conjugate vaccine
AU2002309706A1 (en) 2001-05-11 2002-11-25 Aventis Pasteur, Inc. Novel meningitis conjugate vaccine
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
CN1410532A (zh) * 2002-03-21 2003-04-16 上海凡华生物技术有限公司 一种人/山羊肝嵌合模型的建立及其鉴定方法
ES2616180T3 (es) 2002-03-26 2017-06-09 Glaxosmithkline Biologicals Sa Sacáridos modificados con estabilidad mejorada en agua para su uso como medicamento
JP4061960B2 (ja) 2002-04-26 2008-03-19 株式会社日立製作所 コンピュータシステム
CN1428434A (zh) * 2002-11-14 2003-07-09 中国科学院水生生物研究所 一种检测微囊藻产毒的方法
WO2005004909A2 (en) * 2003-05-07 2005-01-20 Aventis Pasteur, Inc. Method of enhanced immunogenicity to meningococcal vaccination
AU2004240558A1 (en) * 2003-05-07 2004-12-02 Aventis Pasteur, Inc. Multivalent meningococcal derivatized polysaccharide-protein conjugates and corresponding vaccines
CN102023212B (zh) * 2010-09-28 2014-04-02 汕头大学医学院 一种流感病毒神经氨酸酶抗体的快速检测方法

Also Published As

Publication number Publication date
RU2371725C2 (ru) 2009-10-27
CN1981195A (zh) 2007-06-13
EP3035056A1 (en) 2016-06-22
ES2353701T3 (es) 2011-03-04
CY1111272T1 (el) 2015-08-05
EP1725872B8 (en) 2011-04-20
EP1725872B1 (en) 2010-11-03
EP2290366A1 (en) 2011-03-02
DE602005024523D1 (de) 2010-12-16
DE602005026635D1 (de) 2011-04-14
ATE487137T1 (de) 2010-11-15
PT1725872E (pt) 2011-02-08
US20080286300A1 (en) 2008-11-20
HK1098192A1 (en) 2007-07-13
JP2011013226A (ja) 2011-01-20
EP1725871B8 (en) 2011-06-15
JP4692852B2 (ja) 2011-06-01
CA2560224C (en) 2014-10-21
SI1725872T1 (sl) 2011-03-31
RU2006136270A (ru) 2008-04-27
CN1981195B (zh) 2012-07-04
WO2005090986A2 (en) 2005-09-29
WO2005090986A3 (en) 2006-04-13
NZ570193A (en) 2010-02-26
US8137680B2 (en) 2012-03-20
JP2007529736A (ja) 2007-10-25
EP1725871A1 (en) 2006-11-29
ATE500510T1 (de) 2011-03-15
BRPI0508890A (pt) 2007-09-11
NZ549907A (en) 2008-10-31
US20080305126A1 (en) 2008-12-11
GB0406013D0 (en) 2004-04-21
US20120171241A1 (en) 2012-07-05
AU2005224459B2 (en) 2011-02-03
AU2011200950A1 (en) 2011-03-24
EP1725871B1 (en) 2011-03-02
CA2560224A1 (en) 2005-09-29
WO2005090985A1 (en) 2005-09-29
AU2005224459A1 (en) 2005-09-29
EP1725872A2 (en) 2006-11-29

Similar Documents

Publication Publication Date Title
GB0406013D0 (en) Analysis of saccharide vaccines without interference
EP2277537A3 (en) Neisseria meningitidis conjugate combination vaccine
MXPA05007886A (es) Vacunas para la mucosa con adyuvante de quitosan y antigenos para meningococo.
ATE552844T1 (de) Injizierbarer impfstoff gegen multiple meningokokken-serogruppen
GEP20053691B (en) Multivalent Meningococcal Polysaccharide-Protein Conjugate Vaccine
PT1235589E (pt) Composições compreendendo antigénios da neisseria meningitidis dos serogrupos b e c, e outro antigénio
RU2007102016A (ru) Пространственный анализ конъюгатов сахаридов с помощью gpc и sec-mals
EA200801368A1 (ru) Конъюгатные вакцины
WO2002083711A3 (en) Molecular mimetics of meningococcal b epitopes which elicit functionally active antibodies
BR9813930A (pt) antìgeno neisserial
ATE545659T1 (de) Hypo- und hyperacetylierte meningokokken- kapselsaccharide
AU2457100A (en) Enhancement of bactericidal activity of neisseria antigens with oligonucleotidescontaining cg motifs
WO2005105140A3 (en) Meningococcal conjugate vaccination
WO2004103400A3 (en) Multivalent meningococcal derivatized polysaccharide-protein conjugates and corresponding vaccines
GB0500787D0 (en) Integration of meningococcal conjugate vaccination
WO2005000345A3 (en) Immunization method against neisseria meningitidis serogroups a and c
WO2006034320A3 (en) Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine
WO2006026689A3 (en) Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine